What does this research mean for the field?

Standardized EuroFlow-based next-generation flow cytometry for minimal residual disease (MRD) detection is feasible in routine clinical practice and confirms that undetectable MRD is associated with significantly fewer relapses in multiple myeloma. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

To evaluate the feasibility, clinical utility, and immune correlates of standardized next-generation flow cytometry for minimal residual disease detection in routine multiple myeloma care.

September 5, 2026HaematologicaOpen Access

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience

View Full Paper

Ask AI

Bookmark

Authors

CBCirino BottaDepartment of Health ARAndrea RizzutoAzienda ospedaliera "Bianchi-Melacrino-Morelli"MSMaria SpecialeUniversity of Palermo

Discussion

Member takes

Implication

Cohort study reveals lower relapse rates and distinct immune signatures with undetectable minimal residual disease in multiple myeloma, confirming standardized flow cytometry feasibility.

Key Points

To evaluate the feasibility, clinical utility, and immune correlates of standardized next-generation flow cytometry for minimal residual disease detection in routine multiple myeloma care.
Analyzed 97 minimal residual disease (MRD) assessments from 74 multiple myeloma patients (58 transplant-eligible) in a single-center real-world cohort between December 2021 and February 2024.
Used two CE-IVD-approved EuroFlow tubes targeting at least 2 million events per sample to achieve a median analytical sensitivity of 10⁻⁵ after patients reached very good partial response or better.
Undetectable MRD was reached in 45% of evaluations; over a median follow-up of 19 months, 1 relapse occurred in the undetectable MRD group compared to 15 relapses and 3 deaths in persistent MRD patients.
Immunophenotypic profiling demonstrated bone marrow immune remodeling, characterized by an elevated granulocyte-to-lymphocyte ratio and a reduced frequency of CD56dim natural killer cells.

Cite This Study

Botta et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4726b95aff0620ec1c3 https://doi.org/10.3324/haematol.2026.300864

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals lower relapse rates and distinct immune signatures with undetectable minimal residual disease in multiple myeloma, confirming standardized flow cytometry feasibility.

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider